WCM
VIR icon

Wedge Capital Management’s Vir Biotechnology VIR Stock Holding History

Wedge Capital Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-123,084
Closed -$3.02M – 524
2023
Q2 		$3.02M Buy
123,084
+112,659
+1,081% +$2.83M 0.05% 326
2023
Q1 		$243K Buy
10,425
+1,223
+13% +$31.3K ﹤0.01% 377
2022
Q4 		$233K Buy
+9,202
New +$226K ﹤0.01% 380

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wedge Capital Management's VIR Position: Q3 2023 in Review

Wedge Capital Management sold out of Vir Biotechnology (VIR) in Q3 2023, closing a stake of 123,084 shares — an estimated $3.02M sold.

Wedge Capital Management first reported a position in VIR in Q4 2022 and held it in 3 quarters. The position peaked at $3.02M in Q2 2023. 214 funds tracked by Wall St. Rank hold VIR as of Q3 2023.

  • Wedge Capital Management reported no remaining Vir Biotechnology position as of Q3 2023 after selling out during the quarter.
  • Wedge Capital Management sold 123,084 Vir Biotechnology shares in Q3 2023, an estimated $3.02M.
  • Wedge Capital Management first reported a position in Vir Biotechnology in Q4 2022 and held it in 3 quarters.
  • Wedge Capital Management's Vir Biotechnology position peaked at $3.02M in Q2 2023.
  • 214 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2023.

Based on Wedge Capital Management's 13F filing for Q3 2023, filed 13 Oct 2023.